The KLF4 Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted polyclonal cell population engineered from the human Ca Ski cervical squamous cell carcinoma line to ablate KLF4 (Kr??ppel-like factor 4) function. This heterogeneous knockout pool results from Cas9-induced inactivation of the target locus across the cell population, providing a loss-of-function model without clonal selection. The polyclonal format maintains cellular diversity and is optimized for functional studies requiring a physiologically mixed genetic background. Transient delivery of Cas9 and guide RNA yields broad gene disruption, enabling robust interrogation of KLF4 biology.
The parental Ca Ski cell line originates from an epidermoid cervical carcinoma metastatic to the small intestine and contains integrated HPV16 DNA, a defining feature of HPV-driven cervical cancers. Ca Ski cells express viral oncoproteins E6 and E7, which inactivate p53 and pRb, respectively, and retain epithelial morphology, making them a standard model for HPV16-positive cervical carcinoma. Their metastatic origin further enhances relevance for studying invasive behavior and the molecular underpinnings of cervical cancer progression.
KLF4 is a zinc-finger transcription factor with context-dependent tumor-suppressive and oncogenic activities. It directly regulates genes controlling cell cycle (CDKN1A/p21, CCND1/cyclin D1), apoptosis (BCL2, BAX), and differentiation (CDH1/E-cadherin). Upstream, KLF4 is activated by p53, SP1, and TGF-??1, and repressed by MEK/ERK signaling and miR-145. It physically interacts with p300/CBP, HDAC1, SOX2, and OCT4. In cervical epithelial cells, KLF4 functions predominantly as a tumor suppressor by inducing p21 and E-cadherin while antagonizing Wnt/??-catenin and PI3K/AKT pathways.
Knockout of KLF4 in Ca Ski cells disrupts its transcriptional control, predicted to enhance proliferation, survival, and motility??hallmarks of cervical cancer. This model mirrors the frequent KLF4 downregulation in HPV-driven malignancies, enabling mechanistic dissection of how viral oncoproteins collaborate with loss of KLF4 to promote malignancy. The polyclonal population allows assessment of heterogeneous phenotypic outcomes and facilitates studies of KLF4 intersection with p53, SMAD3, and ??-catenin signaling in a cancer-relevant context.
Research applications include elucidating KLF4??s tumor-suppressive role in HPV16-positive cervical cancer, profiling KLF4-dependent transcriptomes, investigating EMT regulation via E-cadherin and MMP9, and evaluating KLF4-targeted therapeutics. Representative assays encompass western blotting for KLF4, p21, and cyclin D1; RT-qPCR; MTT/BrdU proliferation assays; Annexin V apoptosis detection; transwell migration/invasion; flow cytometry for cell cycle; and E-cadherin immunofluorescence. For further information, please contact Ascent Research.
